Rebisufligene etisparvovec: The first AAV9-mediated SGSH gene therapy approved for the treatment of mucopolysaccharidosis type IIIA (MPS IIIA).
Mucopolysaccharidosis type IIIA (MPS IIIA; Sanfilippo syndrome type A) is a rare lysosomal storage disorder caused by biallelic SGSH pathogenic variants that results in heparan sulfate accumulation and progressive neurodegeneration. Previously, treatment was limited to supportive care. In September 2026, the US Food an...